Late-stage biotech OncoSec Medical (ONCS) has announced that it has entered into purchase agreements for an aggregate 4,608,589 of its shares at an offering …
Some investors might love biotech stocks for their lottery ticket-like returns when a company strikes medical gold. A lottery ticket, however, costs only …
OncoSec Medical (NASDAQ:ONCS) just hit clinical trial results out of the park in the melanoma arena, with a Phase 2 combination trial that …
In a research report sent to investors today, H.C.
In a research report published today, H.C.
In a research note released today, Maxim Group analyst Jason Kolbert reaffirmed a Buy rating on OncoSec Medical (OTC:ONCS) with a $3 price …
In a research note published today, H.C.
In a research note issued this morning, H.C.